论文部分内容阅读
有机锗类作为药物最早是由日本浅井一彦于六十年代报道的,其中有代表性的为羧乙基锗氧化物(Ge-132)。七十年代中期,人们通过对Ge-132晶体结构的测定,发现了此化合物具独特的网状结构;且经生理活性研究,发现它是一种新型的抗癌药。近十年来,人们由对Ge-132的研究扩展到对有机锗化合物的研究。目前,一些有机锗化合物的抗癌活性在国内外已普遍得到重视,有些已进入临床研究。本文简要综述这方面的进展。一、倍半氧化物、倍半硫化物类 Ge-132(Ⅰ)是这类化合物中最早合成的。近十年来又陆续合成了一系列化合物,其分子式为O_3(GeR)_2、S_3(GeR)_2(R=烷基或苯基取代的丙酸衍生物、尿嘧啶)。按Ge-132的红
Organic germanium as a drug was first reported by the Japanese Asai Yoshihiko in the sixties, of which carboxyethyl germanium oxide (Ge-132) is a typical example. The mid-seventies, people through the determination of Ge-132 crystal structure, found that this compound has a unique network structure; and the physiological activity of the study and found that it is a new type of anticancer drug. In the last decade, the research on Ge-132 has been extended to the study of organo-germanium compounds. At present, the anticancer activity of some organogermanium compounds has gained universal attention at home and abroad, and some of them have entered clinical studies. This article briefly summarizes the progress in this area. First, the sesquioxide, sesqui sulfide Ge-132 (Ⅰ) is the first of these compounds synthesized. In the recent ten years, a series of compounds have been synthesized one after another. Their molecular formulas are O_3 (GeR) _2 and S_3 (GeR) _2 (R = alkyl or phenyl substituted propionic acid derivatives and uracil). Press Ge-132 red